News
Gusacitinib was acquired by Formation Bio (formerly known as TrialSpark) in late 2022 from Asana BioSciences as part of a broader portfolio of investigational medicines.
Business Business briefing for June 25 Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...
Formation has taken gusacitinib into phase 3 development for chronic hand eczema. However, Sanofi is interested in exploring the therapy’s potential “in a new indication not previously studied ...
Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...
New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its subsidiary Libertas Bio has licensed gusacitinib to Sanofi, expanding the ...
Gusacitinib was acquired by Formation Bio in late 2022 from Asana BioSciences as part of a broader portfolio of investigational medicines. This transaction with Sanofi ushers gusacitinib into its next ...
NEW YORK, NY, USA I June 23, 2025 I Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, an ...
The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results